Latest Rosiglitazone Stories
Gilman Law LLP has over 30 years of experience in complex litigation and class actions involving serious defective drugs.
Ennis & Ennis, P.A.
Researchers from Dana-Farber Cancer Institute in Boston and the Scripps Research Institute in Jupiter, Fla., report they have created prototype drugs having powerful anti-diabetic effects, yet apparently free – at least in mice – of dangerous side effects plaguing some current diabetes medications.
In a joint study, scientists from The Scripps Research Institute and Harvard University's Dana-Farber Cancer Institute have established a new class of anti-diabetic compound that targets a unique molecular switch.
NEW YORK, April 5, 2011 /PRNewswire/ -- The latest news on the much publicized Avandia Settlement's is: there is no news.
A new study published on bmj.com today adds to mounting evidence that rosiglitazone - a drug used to treat type 2 diabetes - is associated with an increased risk of major heart problems.
The prevalence of type 2 diabetes is dramatically increasing throughout the world.
An inexpensive type 2 diabetes drug that has been around for more than 15 years works just as well and has fewer side effects than a half-dozen other, mostly newer and more expensive classes of medication used to control the chronic disease.
FAIRFIELD, N.J., Feb. 16, 2011 /PRNewswire/ -- The Lawsuit Settlement Funding Co., Legal-Bay LLC, announced that applications for Avandia pharmaceutical "lawsuit funding" were up over 500% in the month of January alone. The Lawsuit Settlement Funding Co.